Antitumor Activity of Bromelain Encapsulated Nanoparticles on Cancer Cells
Project no. 23892 · Status: Kapanmış · 2022
Summary
<p>Cancer is a group of diseases that can be caused by genetic or environmental factors, which are common today, can occur in any tissue and can spread to surrounding tissues by metastasis. There are many types of cancer. There are multiple forms of treatment for cancer treatment, but since the treatment process also damages healthy cells, it causes a weakening of the patient's immune system. Accordingly, in recent years, in the light of nanotechnological studies, cancer cell-targeted drugs known as smart drugs have attracted attention. Niosome is one of the preferred nanoparticle systems in these studies. </p><p>Bromelain is a protease mixture obtained from the pineapple stem or fruit. Bromelain is widely used for its wound and circulation healing, anti-inflammatory and immunomodular effects. In recent years, it has been shown in many cell types that it has anticancer properties due to its proteolytic activity. In this study, bromelain was encapsulated into niosomes with 32±2.9% efficiency for the treatment of breast cancer, which is the most common type of cancer in women. Niosome encapsulation, It also protected the enzymatic activity of bromelain by preventing chemical and physical degradation during transport of bromelain to the target site. Specific targeting of niosome-encapsulated bromelain to HER2+ positive SKBR-3 cell line was performed by trastuzumab (herceptin) conjugation. DLS, FTIR, XPS, TEM were used for particle characterization. Empty niosomes (Nio) showed particle size of 134,3±8,1nm, Bromelain loaded niosomes (Nio-Br) showed particle size of 165,6±11,5nm. It was observed that the zeta potential value associated with particle stabilization increased with bromelain loading and trastuzumab conjugation steps. As a result of TEM analysis, it was shown that morphologically spherical and targeted sizes of niosomes of approximately 100nm were synthesized. FTIR and XPS analyzes were performed to confirm pegylation and trastuzumab conjugation.</p>